|
|
Article: MaxCyte, Angiogene Agree To Develop Heart Failure Treatment.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
MaxCyte Inc. entered a research agreement with Angiogene Inc. to develop a recuperative treatment for congestive heart failure caused by myocardial infarction using MaxCyte's GT cell-loading system.
"We're developing a nonviral cell-loading system, and we're perfecting it for them so they can use the transformed cells, or those transfected with the gene that promotes blood cell growth, for their clinical work," said MaxCyte President and CEO Douglas Doerfler.
Although specific financial terms were not disclosed, Doerfler said his company would receive an up-front payment followed by payments triggered by milestones.
...